BioMarin Pharmaceuticals BMRN Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's impairment charges?
- BioMarin Pharmaceuticals (BMRN) reported impairment charges of $0 in Q1 2026.
- How has BioMarin Pharmaceuticals's impairment charges changed year-over-year?
- BioMarin Pharmaceuticals's impairment charges decreased by 100.0% year-over-year, from $2.97M to $0.
- What does impairment charges mean?
- Non-cash write-downs of assets that have lost value.
- How do you interpret impairment charges?
- High impairment charges often signal poor past acquisition performance or shifts in market viability for specific products.
- How does impairment charges compare across companies?
- Common in biotech when clinical trials fail or commercial products underperform expectations.